逆转结肠癌奥沙利铂耐药的研究进展
Research Progress on Reversing Oxaliplatin Resistance in Colon Cancer
DOI: 10.12677/ACM.2023.1381779, PDF,    科研立项经费支持
作者: 荣远哲*：西安医学院研究生院，陕西 西安；刘 屹：陕西省人民医院肿瘤内科，陕西 西安；王建华#：陕西省人民医院普外二科，陕西 西安
关键词: 结肠癌；奥沙利铂；化疗耐药；逆转耐药；Colon Cancer； Oxaliplatin； Chemotherapy Resistance； Reversal of Drug Resistance
摘要: 结直肠癌是在全球发病率居第三位，死亡率居第二位的恶性肿瘤，严重威胁人类的身体健康。化疗是结肠癌常见的治疗方法，化疗耐药是影响结肠癌患者疗效和预后的主要因素。奥沙利铂作为结肠癌术后辅助及晚期一线治疗的基石药物，为广大结肠癌患者带来生存获益，但其耐药也是不可避免的。这也是结肠癌患者临床化疗失败并导致肿瘤复发和转移的主要原因之一。因此，探究结肠癌奥沙利铂耐药的分子机制并逆转其耐药，对提高结肠癌患者治疗疗效、改善患者预后具有重大意义。本文将较为详尽地阐明近年来关于逆转结肠癌奥沙利铂耐药的最新研究进展，以为临床进一步治疗及研究提供参佐。
Abstract: Colorectal cancer is a malignant tumor with the third highest incidence and the second highest mortality in the world, which is a serious threat to the health of patients. Chemotherapy is a com-mon treatment for colon cancer, and chemotherapy resistance is the main factor affecting the effi-cacy and prognosis of patients with colon cancer. As a cornerstone drug of postoperative adjuvant and advanced line therapy for colon cancer, oxaliplatin brings survival benefits for the majority of colon cancer patients, but its drug resistance is also inevitable. This is also the main reason for the failure of clinical chemotherapy in patients with colon cancer and leading to tumor recurrence and metastasis. Therefore, to explore the molecular mechanism of oxaliplatin resistance in colon cancer and reverse its drug resistance is of great significance to improve the therapeutic efficacy and prognosis of patients with colon cancer. This article will clarify in detail the latest research progress on reversing oxaliplatin resistance in colon cancer in recent years, so as to provide reference for further clinical treatment and research.
文章引用：荣远哲, 刘屹, 王建华. 逆转结肠癌奥沙利铂耐药的研究进展[J]. 临床医学进展, 2023, 13(8): 12687-12695. https://doi.org/10.12677/ACM.2023.1381779

参考文献

[1] Arnold, M., Abnet, C.C., Neale, R.E., et al. (2020) Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastro-enterology, 159, 335-349.e15. [Google Scholar] [CrossRef] [PubMed]
[2] (2020) Erratum: Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 70, 313. [Google Scholar] [CrossRef] [PubMed]
[3] Zhou, J., Zheng, R., Zhang, S., et al. (2021) Colorectal Cancer Burden and Trends: Comparison between China and Major Burden Countries in the World. Chinese Journal of Cancer Research, 33, 1-10. [Google Scholar] [CrossRef] [PubMed]
[4] Chuang, J.P., Tsai, H.L., Chen, P.J., et al. (2022) Com-prehensive Review of Biomarkers for the Treatment of Locally Advanced Colon Cancer. Cells, 11, Article 3744. [Google Scholar] [CrossRef] [PubMed]
[5] Fabregas, J.C., Ramnaraign, B. and George, T.J. (2022) Clinical Up-dates for Colon Cancer Care in 2022. Clinical Colorectal Cancer, 21, 198-203. [Google Scholar] [CrossRef] [PubMed]
[6] Yu, T., An, Q., Cao, X.L., et al. (2020) GOLPH3 Inhibition Re-verses Oxaliplatin Resistance of Colon Cancer Cells via Suppression of PI3K/AKT/mTOR Pathway. Life Sciences, 260, Article 118294. [Google Scholar] [CrossRef] [PubMed]
[7] Arredondo, J., Baixauli, J., Pastor, C., et al. (2017) Mid-Term On-cologic Outcome of a Novel Approach for Locally Advanced Colon Cancer with Neoadjuvant Chemotherapy and Sur-gery. Clinical and Translational Oncology, 19, 379-385. [Google Scholar] [CrossRef] [PubMed]
[8] Park, G.B., Chung, Y.H. and Kim, D. (2017) 2-Deoxy-D-Glucose Suppresses the Migration and Reverses the Drug Resistance of Colon Cancer Cells through ADAM Expression Regulation. Anti-Cancer Drugs, 28, 410-420. [Google Scholar] [CrossRef] 
[9] Guo, C., Ma, J., Deng, G., et al. (2017) ZEB1 Promotes Oxaliplatin Resistance through the Induction of Epithelial-Mesenchymal Transition in Colon Cancer Cells. Journal of Cancer, 8, 3555-3566. [Google Scholar] [CrossRef] [PubMed]
[10] Zhang, C., Liu, X., Jin, S., et al. (2022) Ferroptosis in Cancer Therapy: A Novel Approach to Reversing Drug Resistance. Molecular Cancer, 21, Article 47. [Google Scholar] [CrossRef] [PubMed]
[11] Liu, R., Chen, Y., Liu, G., et al. (2020) PI3K/AKT Pathway as a Key Link Modulates the Multidrug Resistance of Cancers. Cell Death & Disease, 11, Article 797. [Google Scholar] [CrossRef] [PubMed]
[12] Zhou, F., Wang, L., Jin, K., et al. (2021) RecQ-Like Helicase 4 (RECQL4) Exacerbates Resistance to Oxaliplatin in Colon Adenocarcinoma via Activation of the PI3K/AKT Signaling Pathway. Bioengineered, 12, 5859-5869. [Google Scholar] [CrossRef] [PubMed]
[13] Lu, H., Fang, E.F., Sykora, P., et al. (2014) Senescence In-duced by RECQL4 Dysfunction Contributes to Rothmund-Thomson Syndrome Features in Mice. Cell Death & Disease, 5, e1226. [Google Scholar] [CrossRef] [PubMed]
[14] Popuri, V., Tadokoro, T., Croteau, D.L., et al. (2013) Hu-man RECQL5: Guarding the Crossroads of DNA Replication and Transcription and Providing Backup Capability. Criti-cal Reviews in Biochemistry and Molecular Biology, 48, 289-299. [Google Scholar] [CrossRef] [PubMed]
[15] Arriagada, C., Luchsinger, C., González, A.E., et al. (2019) The Knocking Down of the Oncoprotein Golgi Phosphoprotein 3 in T98G Cells of Glioblastoma Multiforme Disrupts Cell Migration by Affecting Focal Adhesion Dynamics in a Focal Adhesion Kinase-Dependent Manner. PLOS ONE, 14, e0212321. [Google Scholar] [CrossRef] [PubMed]
[16] Lu, J., Zhong, F., Sun, B., et al. (2019) Diagnostic Utility of Serum Golgi Phosphoprotein 3 in Bladder Cancer Patients. Medical Science Monitor, 25, 6736-6741. [Google Scholar] [CrossRef] 
[17] Rizzo, R., Parashuraman, S., D’Angelo, G., et al. (2017) GOLPH3 and Oncogenesis: What Is the Molecular Link? Tissue and Cell, 49, 170-174. [Google Scholar] [CrossRef] [PubMed]
[18] Tang, S., Pan, H., Wei, W., et al. (2017) GOLPH3: A Novel Bi-omarker That Correlates with Poor Survival and Resistance to Chemotherapy in Breast Cancer. Oncotarget, 8, 105155-105169. [Google Scholar] [CrossRef] [PubMed]
[19] Liu, Y., Sun, Y. and Zhao, A. (2017) Mi-croRNA-134 Suppresses Cell Proliferation in Gastric Cancer Cells via Targeting of GOLPH3. Oncology Reports, 37, 2441-2448. [Google Scholar] [CrossRef] [PubMed]
[20] Zhou, X., Xue, P., Yang, M., et al. (2014) Protein Kinase D2 Promotes the Proliferation of Glioma Cells by Regulating Golgi Phosphoprotein 3. Cancer Letters, 355, 121-129. [Google Scholar] [CrossRef] [PubMed]
[21] Zhang, P., Chen, Z., Ning, K., et al. (2017) Inhibition of B7-H3 Reverses Oxaliplatin Resistance in Human Colorectal Cancer Cells. Biochemical and Biophysical Research Communica-tions, 490, 1132-1138. [Google Scholar] [CrossRef] [PubMed]
[22] Hui, B., Lu, C., Wang, J., et al. (2022) Engineered Exosomes for Co-Delivery of PGM5-AS1 and Oxaliplatin to Reverse Drug Resistance in Colon Cancer. Journal of Cellular Physiology, 237, 911-933. [Google Scholar] [CrossRef] [PubMed]
[23] Xie, C., Zhang, L.Z., Chen, Z.L., et al. (2020) A hMTR4-PDIA3P1-miR-125/124-TRAF6 Regulatory Axis and Its Function in NF kappa B Signaling and Chemo-resistance. Hepatology, 71, 1660-1677. [Google Scholar] [CrossRef] [PubMed]
[24] Cai, Q., Wang, S., Jin, L., et al. (2019) Long Non-Coding RNA GBCDRlnc1 Induces Chemoresistance of Gallbladder Cancer Cells by Activating Autophagy. Molecular Cancer, 18, Article No. 82. [Google Scholar] [CrossRef] [PubMed]
[25] Li, Q., Sun, H., Luo, D., et al. (2021) Lnc-RP11-536 K7.3/SOX2/HIF-1α Signaling Axis Regulates Oxaliplatin Resistance in Patient-Derived Colorectal Can-cer Organoids. Journal of Experimental & Clinical Cancer Research, 40, Article No. 348. [Google Scholar] [CrossRef] [PubMed]
[26] Sun, W.L., Kang, T., Wang, Y.Y., et al. (2019) Long Noncoding RNA OIP5-AS1 Targets Wnt-7b to Affect Glioma Progression via Modulation of miR-410. Bioscience Reports, 39, BSR20180395. [Google Scholar] [CrossRef] 
[27] Liang, J., Tian, X.F. and Yang, W. (2020) Effects of Long Non-Coding RNA Opa-Interacting Protein 5 Antisense RNA 1 on Colon Cancer Cell Resistance to Oxaliplatin and Its Regulation of microRNA-137. World Journal of Gastroenterology, 26, 1474-1489. [Google Scholar] [CrossRef] [PubMed]
[28] Li, P.L., Zhang, X., Wang, L.L., et al. (2015) MicroRNA-218 Is a Prognostic Indicator in Colorectal Cancer and Enhances 5-Fluorouracil-Induced Apoptosis by Targeting BIRC5. Car-cinogenesis, 36, 1484-1493. [Google Scholar] [CrossRef] [PubMed]
[29] Zhang, Z., Ma, J., Luan, G., et al. (2015) MiR-506 Suppresses Tumor Proliferation and Invasion by Targeting FOXQ1 in Nasopharyngeal Carcinoma. PLOS ONE, 10, e0122851. [Google Scholar] [CrossRef] [PubMed]
[30] Zhou, H., Lin, C., Zhang, Y., et al. (2017) miR-506 Enhances the Sensitivity of Human Colorectal Cancer Cells to Oxaliplatin by Suppressing MDR1/P-gp Expression. Cell Prolifera-tion, 50, e12341. [Google Scholar] [CrossRef] [PubMed]
[31] Oh, E.T, Kim, J.W., Kim, J.M., et al. (2016) NQO1 Inhib-its Proteasome-Mediated Degradation of HIF-1α. Nature Communications, 7, Article No. 13593. [Google Scholar] [CrossRef] [PubMed]
[32] Tang, Y.A., Chen, Y.F., Bao, Y., et al. (2018) Hypoxic Tumor Micro-environment Activates GLI2 via HIF-1α and TGF-β2 to Promote Chemoresistance in Colorectal Cancer. Proceedings of the National Academy of Sciences of the United States of America, 115, E5990-E5999. [Google Scholar] [CrossRef] [PubMed]
[33] Xu, K., Zhan, Y., Yuan, Z., et al. (2019) Hypoxia Induces Drug Resistance in Colorectal Cancer through the HIF-1α/miR-338-5p/IL-6 Feedback Loop. Molecular Therapy, 27, 1810-1824. [Google Scholar] [CrossRef] [PubMed]
[34] Wei, T.T., Lin, Y.T., Tang, S.P., et al. (2020) Metabolic Target-ing of HIF-1α Potentiates the Therapeutic Efficacy of Oxaliplatin in Colorectal Cancer. Oncogene, 39, 414-427. [Google Scholar] [CrossRef] [PubMed]
[35] Elaskalani, O., Razak, N.B., Falasca, M., et al. (2017) Epitheli-al-Mesenchymal Transition as a Therapeutic Target for Overcoming Chemoresistance in Pancreatic Cancer. World Jour-nal of Gastrointestinal Oncology, 9, 37-41. [Google Scholar] [CrossRef] [PubMed]
[36] Lazarova, D. and Bordonaro, M. (2017) ZEB1 Mediates Drug Re-sistance and EMT in p300-Deficient CRC. Journal of Cancer, 8, 1453-1459. [Google Scholar] [CrossRef] [PubMed]
[37] Zhang, P., Sun, Y. and Ma, L. (2015) ZEB1: At the Crossroads of Epitheli-al-Mesenchymal Transition, Metastasis and Therapy Resistance. Cell Cycle, 14, 481-487. [Google Scholar] [CrossRef] [PubMed]
[38] Nakayama, M. and Oshima, M. (2019) Mutant p53 in Colon Cancer. Journal of Molecular Cell Biology, 11, 267-276. [Google Scholar] [CrossRef] [PubMed]
[39] Therachiyil, L., Haroon, J., Sahir, F., et al. (2020) Dysregulated Phos-phorylation of p53, Autophagy and Stemness Attributes the Mutant p53 Harboring Colon Cancer Cells Impaired Sensi-tivity to Oxaliplatin. Frontiers in Oncology, 10, Article 1744. [Google Scholar] [CrossRef] [PubMed]
[40] Wu, J., Liang, Y., Tan, Y., et al. (2020) CDK9 Inhibitors Reactivate p53 by Downregulating iASPP. Cellular Signalling, 67, Ar-ticle 109508. [Google Scholar] [CrossRef] [PubMed]
[41] Huang, Y., Liu, N., Liu, J., et al. (2019) Mutant p53 Drives Cancer Chemotherapy Resistance Due to Loss of Function on Activating Transcription of PUMA. Cell Cycle, 18, 3442-3455. [Google Scholar] [CrossRef] [PubMed]
[42] He, C., Li, L., Guan, X., et al. (2017) Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy. Chemo-therapy, 62, 43-53. [Google Scholar] [CrossRef] [PubMed]
[43] Kanno, Y., Watanabe, M., Kimura, T., et al. (2014) TRIM29 as a Novel Prostate Basal Cell Marker for Diagnosis of Prostate Cancer. Acta Histochemica, 116, 708-712. [Google Scholar] [CrossRef] [PubMed]
[44] Lei, G., Liu, S., Yang, X., et al. (2021) TRIM29 Reverses Oxali-platin Resistance of P53 Mutant Colon Cancer Cell. Canadian Journal of Gastroenterology and Hepatology, 2021, Arti-cle ID: 8870907. [Google Scholar] [CrossRef] [PubMed]
[45] Zhou, Y., Tian, T., Zhu, Y., et al. (2017) Exosomes Transfer among Different Species Cells and Mediating miRNAs Delivery. Journal of Cellular Biochemistry, 118, 4267-4274. [Google Scholar] [CrossRef] [PubMed]
[46] Zheng, Z., Li, Z., Xu, C., et al. (2019) Folate-Displaying Exosome Mediated Cytosolic Delivery of siRNA Avoiding Endosome Trapping. Journal of Controlled Release, 311-312, 43-49. [Google Scholar] [CrossRef] [PubMed]
[47] Ma, Y., Temkin, S.M., Hawkridge, A.M., et al. (2018) Fatty Acid Oxidation: An Emerging Facet of Metabolic Transformation in Cancer. Cancer Letters, 435, 92-100. [Google Scholar] [CrossRef] [PubMed]
[48] Lin, D., Zhang, H., Liu, R., et al. (2021) iRGD-Modified Exo-somes Effectively Deliver CPT1A siRNA to Colon Cancer Cells, Reversing Oxaliplatin Resistance by Regulating Fatty Acid Oxidation. Molecular Oncology, 15, 3430-3446. [Google Scholar] [CrossRef] [PubMed]
[49] Yang, L., Hu, Y., Zhou, G., et al. (2020) Erianin Suppresses Hepa-tocellular Carcinoma Cells through Down-Regulation of PI3K/AKT, p38 and ERK MAPK Signaling Pathways. Biosci-ence Reports, 40, BSR20193137. [Google Scholar] [CrossRef] 
[50] Chen, P., Wu, Q., Feng, J., et al. (2020) Erianin, a Novel Dibenzyl Compound in Dendrobium Extract, Inhibits Lung Cancer Cell Growth and Migration via Calcium/Calmodulin-Dependent Ferroptosis. Signal Transduction and Targeted Therapy, 5, Article No. 51. [Google Scholar] [CrossRef] [PubMed]
[51] Sun, Y., Li, G., Zhou, Q., et al. (2020) Dual Targeting of Cell Growth and Phagocytosis by Erianin for Human Colorectal Cancer. Drug Design, Development and Therapy, 14, 3301-3313. [Google Scholar] [CrossRef] 
[52] Su, C., Liu, S., Ma, X., et al. (2021) The Effect and Mechanism of Erianin on the Reversal of Oxaliplatin Resistance in Human Colon Cancer Cells. Cell Biology Internation-al, 45, 2420-2428. [Google Scholar] [CrossRef] [PubMed]
[53] Xu, F.Y., Shang, W.Q., Yu, J.J., et al. (2016) The An-titumor Activity Study of Ginsenosides and Metabolites in Lung Cancer Cell. American Journal of Translational Re-search, 8, 1708-1718.
[54] Ma, J., Gao, G., Lu, H., et al. (2019) Reversal Effect of Ginsenoside Rh2 on Oxali-platin-Resistant Colon Cancer Cells and Its Mechanism. Experimental and Therapeutic Medicine, 18, 630-636. [Google Scholar] [CrossRef] [PubMed]
[55] Chun, J., Li, R.J., Cheng, M.S., et al. (2015) Alantolactone Selectively Suppresses STAT3 Activation and Exhibits Potent Anticancer Activity in MDA-MB-231 Cells. Cancer Letters, 357, 393-403. [Google Scholar] [CrossRef] [PubMed]
[56] Cao, P., Xia, Y., He, W., et al. (2019) Enhancement of Oxali-platin-Induced Colon Cancer Cell Apoptosis by Alantolactone, a Natural Product Inducer of ROS. International Journal of Biological Sciences, 15, 1676-1684. [Google Scholar] [CrossRef] [PubMed]
[57] Baricevic, I., Roberts, D.L. and Renehan, A.G. (2014) Chronic Insulin Ex-posure Does Not Cause Insulin Resistance but Is Associated with Chemo-Resistance in Colon Cancer Cells. Hormone and Metabolic Research, 46, 85-93. [Google Scholar] [CrossRef] [PubMed]
[58] Yang, I.P., Miao, Z.F., Huang, C.W., et al. (2019) High Blood Sugar Levels but Not Diabetes Mellitus Significantly Enhance Oxaliplatin Chemoresistance in Patients with Stage III Colorectal Cancer Receiving Adjuvant FOLFOX6 Chemotherapy. Therapeutic Advances in Medical Oncology, 11. [Google Scholar] [CrossRef] [PubMed]
[59] Liu, C., Liu, Q., Yan, A., et al. (2020) Metformin Revert Insu-lin-Induced Oxaliplatin Resistance by Activating Mitochondrial Apoptosis Pathway in Human Colon Cancer HCT116 Cells. Cancer Medicine, 9, 3875-3884. [Google Scholar] [CrossRef] [PubMed]
[60] Zhang, J., Chen, Y., Luo, H., et al. (2018) Recent Update on the Pharma-cological Effects and Mechanisms of Dihydromyricetin. Frontiers in Pharmacology, 9, Article 1204. [Google Scholar] [CrossRef] [PubMed]
[61] Wang, Z., Sun, X., Feng, Y., et al. (2021) Dihydromyricetin Re-verses MRP2-Induced Multidrug Resistance by Preventing NF-κB-Nrf2 Signaling in Colorectal Cancer Cell. Phytomedi-cine, 82, Article 153414. [Google Scholar] [CrossRef] [PubMed]

为你推荐